A Phase I, Multi-Center, Non-Randomized, Open Label, Parallel-Group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Subjects with Severe Renal Impairment compared to a Control Group

To assess the influence of severe renal impairment on thepharmacokinetics and safety of once daily oral treatment with160 mg regorafenib (3 weeks on/1 week off) in subjects with solidmalignant tumors.

Study Number: 

PH 235013

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.